TY - JOUR
T1 - Experience with intraoperative use of artificial pancreas during local resection of insulinoma
AU - Asano, Yukio
AU - Kato, Hiroyuki
AU - Arakawa, Satoshi
AU - Ito, Masahiro
AU - Shimura, Masahiro
AU - Koike, Daisuke
AU - Hayashi, Chihiro
AU - Kawai, Toki
AU - Higashiguchi, Takahiko
AU - Horiguchi, Akihiko
N1 - Publisher Copyright:
© 2022, Japanese Society of Gastroenterology.
PY - 2022/10
Y1 - 2022/10
N2 - A 50-year-old woman was hospitalized for fainting caused by hypoglycemia. Her blood glucose level was low (40 mg/dL), immunoreactive insulin was 16.9 μU/mL, and C-peptide level was high (4.8 ng/mL). Computed tomography and magnetic resonance imaging revealed a 7-mm tumor in the uncinate process of the pancreas. A selective arterial calcium injection test indicated an increase in the superior mesenteric artery. Insulinoma of the uncinate process of the pancreas was diagnosed, and tumor enucleation was planned using an artificial pancreas for intraoperative and postoperative blood glucose control. Hypoglycemia (blood glucose, 38 mg/dL) was observed from the onset of surgery. An artificial pancreas cannot be used if the blood glucose level is ≤ 70 mg/dL; thus, continuous glucose infusion was administered. The sudden rise in blood glucose prompted insulin infusion from the device, causing hypoglycemia. Controlling blood glucose levels is challenging when introducing the artificial pancreas. However, altering the device’s blood glucose control algorithm controlled the fluctuating blood glucose level, and, intraoperative average blood glucose was raised to 94.8 ± 21.1 mg/dL, thereby avoiding hypoglycemia, that is, a blood glucose level of ≤ 70 mg/dL. We report a case in which an artificial pancreas was used for glycemic control during surgery for an insulinoma.
AB - A 50-year-old woman was hospitalized for fainting caused by hypoglycemia. Her blood glucose level was low (40 mg/dL), immunoreactive insulin was 16.9 μU/mL, and C-peptide level was high (4.8 ng/mL). Computed tomography and magnetic resonance imaging revealed a 7-mm tumor in the uncinate process of the pancreas. A selective arterial calcium injection test indicated an increase in the superior mesenteric artery. Insulinoma of the uncinate process of the pancreas was diagnosed, and tumor enucleation was planned using an artificial pancreas for intraoperative and postoperative blood glucose control. Hypoglycemia (blood glucose, 38 mg/dL) was observed from the onset of surgery. An artificial pancreas cannot be used if the blood glucose level is ≤ 70 mg/dL; thus, continuous glucose infusion was administered. The sudden rise in blood glucose prompted insulin infusion from the device, causing hypoglycemia. Controlling blood glucose levels is challenging when introducing the artificial pancreas. However, altering the device’s blood glucose control algorithm controlled the fluctuating blood glucose level, and, intraoperative average blood glucose was raised to 94.8 ± 21.1 mg/dL, thereby avoiding hypoglycemia, that is, a blood glucose level of ≤ 70 mg/dL. We report a case in which an artificial pancreas was used for glycemic control during surgery for an insulinoma.
UR - http://www.scopus.com/inward/record.url?scp=85135963045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135963045&partnerID=8YFLogxK
U2 - 10.1007/s12328-022-01679-5
DO - 10.1007/s12328-022-01679-5
M3 - Article
C2 - 35969322
AN - SCOPUS:85135963045
SN - 1865-7257
VL - 15
SP - 1012
EP - 1017
JO - Clinical Journal of Gastroenterology
JF - Clinical Journal of Gastroenterology
IS - 5
ER -